利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

34 records (took 0.029 seconds)

    Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
    3.
    发明授权
    Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients 失效
    抗T-BAM（CD40-L）单克隆抗体5C8治疗非移植受者再灌注损伤的治疗应用

    公开(公告)号：US06340459B1

    公开(公告)日：2002-01-22

    申请号：US08637323

    申请日：1996-04-22

    Applicant: Michael J. Yellin ,  Seth Lederman ,  Leonard Chess

    Inventor： Michael J. Yellin ,  Seth Lederman ,  Leonard Chess

    IPC: A61K39395

    CPC classification number: G01N33/576 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70575 ,  C07K14/70578 ,  C07K16/2875 ,  C07K16/2878 ,  C07K2317/73 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/6863 ,  G01N2333/70578 ,  Y02A50/401

    Abstract: Activation of cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the cells with an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Activation of cells bearing CD40 on their surface by CD40 ligand in a subject is inhibited by administering to the subject an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Reperfusion injury, in an non-transplant recipient, is a condition associated with CD40 ligand-induced activation of CD40-bearing cells. Therefore, reperfusion injury can be treated by the administration of anti-human CD40L monoclonal antibodies, such as those described herein (e.g. 5c8 mAb).

    Abstract translation: 通过使细胞与能够抑制CD40配体和细胞之间的相互作用的试剂以有效抑制细胞活化的量接触来抑制CD40配体在其细胞表面上带有CD40的细胞的活化。 通过向受试者施用能够抑制CD40配体和细胞之间的相互作用的试剂，以有效抑制细胞活化的量来抑制受试者中CD40配体在其表面上带有CD40的细胞的活化。 在非移植受体中的再灌注损伤是与CD40配体诱导的携带CD40的细胞的活化相关的病症。 因此，可以通过施用抗人CD40L单克隆抗体（例如本文所述的那些（例如5c8mAb））来治疗再灌注损伤。

    Protein recognized by an antibody that specifically binds an epitope that is specifically bound by monoclonal antibody 5c8.
    5.
    发明授权
    Protein recognized by an antibody that specifically binds an epitope that is specifically bound by monoclonal antibody 5c8. 失效
    通过特异性结合由单克隆抗体5c8特异性结合的表位的抗体识别的蛋白质。

    公开(公告)号：US06793924B2

    公开(公告)日：2004-09-21

    申请号：US10183903

    申请日：2002-06-25

    Applicant: Seth Lederman ,  Leonard Chess ,  Michael J. Yellin

    Inventor： Seth Lederman ,  Leonard Chess ,  Michael J. Yellin

    IPC: A61K3817

    CPC classification number: C07K14/705 ,  A61K38/00 ,  A61K39/00 ,  A61K47/68 ,  A61K47/6849 ,  A61K51/1039 ,  A61K51/1087 ,  A61K2123/00 ,  C07K14/70575 ,  C07K16/2875 ,  C07K2317/24 ,  C07K2319/00 ,  C12N5/0694 ,  Y02A50/401 ,  Y10S514/885

    Abstract: This invention provides a protein free of cell membranes and other cellular components, said protein being specifically recognized by an antibody that specifically binds an epitope that is specifically bound by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916. This invention further provides a protein that is a fragment of a protein specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916, wherein said fragment is free of cell membranes and other cellular components and comprises an epitope that is specifically bound by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916. This invention also provides a protein free of cell membranes and other cellular components, said protein consisting essentially of an epitope that is specifically bound by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916.

    Abstract translation: 本发明提供了不含细胞膜和其它细胞组分的蛋白质，所述蛋白质由特异性结合由具有ATCC登录号HB 10916的杂交瘤产生的单克隆抗体5c8特异性结合的表位的抗体特异性识别。本发明进一步 提供蛋白质，其是由具有ATCC登录号HB 10916的杂交瘤产生的单克隆抗体5c8特异性识别的蛋白质的片段，其中所述片段不含细胞膜和其它细胞成分，并且包含特异性结合单克隆抗体 抗体5c8由具有ATCC登录号HB 10916的杂交瘤产生。本发明还提供了不含细胞膜和其它细胞成分的蛋白质，所述蛋白质基本上由由具有ATCC的杂交瘤产生的单克隆抗体5c8特异性结合的表位组成 登录号HB 10916。

    Methods for inhibiting the rejection of a transplant organ in a subject with 5C8-specific antibodies
    6.
    发明授权
    Methods for inhibiting the rejection of a transplant organ in a subject with 5C8-specific antibodies 失效
    用5C8特异性抗体抑制受试者的移植器官排斥反应的方法

    公开(公告)号：US06403091B1

    公开(公告)日：2002-06-11

    申请号：US08484130

    申请日：1995-06-07

    Applicant: Seth Lederman ,  Leonard Chess ,  Michael J. Yellin

    Inventor： Seth Lederman ,  Leonard Chess ,  Michael J. Yellin

    IPC: A61K39395

    CPC classification number: C07K14/705 ,  A61K38/00 ,  A61K39/00 ,  A61K47/68 ,  A61K47/6849 ,  A61K51/1039 ,  A61K51/1087 ,  A61K2123/00 ,  C07K14/70575 ,  C07K16/2875 ,  C07K2317/24 ,  C07K2319/00 ,  C12N5/0694 ,  Y02A50/401 ,  Y10S514/885

    Abstract: This invention provides for a method for inhibiting rejection of a transplant organ in a subject which comprises administering to the subject an antibody capable of binding to a protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916. The present invention further provides for a method for inhibiting rejection of a transplant organ in a subject, which comprises administering to the subject a pharmaceutical composition comprising a monoclonal antibody capable of binding to a protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916. In one embodiment of the invention, the transplant organ is a heart, a kidney or a liver. In another embodiment, the monoclonal antibody is 5c8 produced by the hybridoma having ATCC Accession No. HB 10916.

    Abstract translation: 本发明提供了一种抑制受试者移植器官排斥反应的方法，其包括向受试者施用能够结合由具有ATCC登录号HB 10916的杂交瘤产生的单克隆抗体5c8特异性识别的蛋白质的抗体。 本发明还提供了抑制受试者的移植器官的排斥反应的方法，其包括向受试者施用包含能够与由杂交瘤产生的单克隆抗体5c8特异性识别的蛋白质结合的单克隆抗体的药物组合物 具有ATCC保藏号HB 10916.在本发明的一个实施方案中，移植器官是心脏，肾脏或肝脏。 在另一个实施方案中，单克隆抗体是由具有ATCC登录号HB 10916的杂交瘤产生的5c8。

Patent Agency Ranking